HomeCompareGPX vs ABBV

GPX vs ABBV: Dividend Comparison 2026

GPX yields 4.80% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $74.9K in total portfolio value
10 years
GPX
GPX
● Live price
4.80%
Share price
$20.85
Annual div
$1.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.4K
Annual income
$651.98
Full GPX calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — GPX vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGPXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GPX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GPX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GPX
Annual income on $10K today (after 15% tax)
$407.67/yr
After 10yr DRIP, annual income (after tax)
$554.18/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,501.82/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GPX + ABBV for your $10,000?

GPX: 50%ABBV: 50%
100% ABBV50/50100% GPX
Portfolio after 10yr
$64.9K
Annual income
$12,711.87/yr
Blended yield
19.60%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

GPX
Analyst Ratings
4
Buy
2
Hold
Consensus: Buy
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GPX buys
0
ABBV buys
0
No recent congressional trades found for GPX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGPXABBV
Forward yield4.80%3.06%
Annual dividend / share$1.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$27.4K$102.3K
Annual income after 10y$651.98$24,771.77
Total dividends collected$5.7K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: GPX vs ABBV ($10,000, DRIP)

YearGPX PortfolioGPX Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,180$479.62$11,550$430.00$370.00ABBV
2$12,463$501.11$13,472$627.96$1.0KABBV
3$13,858$522.11$15,906$926.08$2.0KABBV
4$15,370$542.55$19,071$1,382.55$3.7KABBV
5$17,009$562.40$23,302$2,095.81$6.3KABBV
6$18,781$581.63$29,150$3,237.93$10.4KABBV
7$20,696$600.22$37,536$5,121.41$16.8KABBV
8$22,763$618.15$50,079$8,338.38$27.3KABBV
9$24,992$635.40$69,753$14,065.80$44.8KABBV
10$27,393$651.98$102,337$24,771.77$74.9KABBV

GPX vs ABBV: Complete Analysis 2026

GPXStock

GP Strategies Corporation provides performance improvement and learning solutions worldwide. The company operates in two segments, Workforce Excellence and Business Transformation Services. The Workforce Excellence segment offers managed learning services, including strategic learning and development consulting; digital learning content design and development solutions; and a suite of learning operations services, such as managed facilitation and delivery, managed training administration and logistics, help desk support, and event and vendor management. This segment also provides engineering and technical services comprising design, development and delivery of technical work-based learning, plant launch initiatives, engineering design and construction management, fabrication, management, operational excellence consulting, chemical demilitarization, homeland security, emergency management support, and asset management and performance improvement consulting, as well as technical documentation services; EtaPRO performance and condition monitoring system, a suite of real-time digital solutions for facilities and power-generating units; and GPiLEARN+ portal, a web-based off-the-shelf delivery format of technical courses. The Business Transformation Services segment offers custom product sales training and service technical training primarily to automotive manufacturers and service technicians; and organizational development solutions, including strategy, leadership, employee engagement and culture consulting, enterprise technology implementation and adoption, and organization design and business performance consulting. It serves companies in the automotive, financial services and insurance, pharmaceutical, oil and gas, power, chemical, electronics and technology, manufacturing, software, retail, healthcare, education, and food and beverage industries, as well as government agencies. GP Strategies Corporation was founded in 1959 and is headquartered in Columbia, Maryland.

Full GPX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this GPX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GPX vs SCHDGPX vs JEPIGPX vs OGPX vs KOGPX vs MAINGPX vs JNJGPX vs MRKGPX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.